Literature DB >> 7306425

Sublingual buprenorphine used postoperatively: clinical observations and preliminary pharmacokinetic analysis.

R E Bullingham, H J McQuay, D Dwyer, M C Allen, R A Moore.   

Abstract

1 Buprenorphine is a long-acting opiate analgesic. This study was designed to investigate the pharmacokinetics of this drug when given by the sublingual route to ten postoperative patients. Plasma levels of buprenorphine were measured by a specific radioimmunoassay. 2 Plasma levels of the drug following sublingual administration of 0.4 mg showed an apparent delay in absorption and then rose slowly to reach low but significant levels by 3 h. There was considerable variation in the time at which peak levels were achieved. The average systemic availability of the drug by this route was estimated to be 30% by 3 h. 3 Analgesic efficacy and duration of sublingual buprenorphine were assessed using demand analgesia. The analgesia was of about 9 h duration, similar to that achieved by parenteral administration of 0.3 mg of the drug to an equivalent group of patients. The sublingual dose caused a significant fall in the postoperatively elevated group of patients. The sublingual dose caused a significant fall in the postoperatively elevated plasma glucose, and prevented any further rise in plasma cortisol. 4 Reasons for the efficacy of the sublingual route are discussed and it is suggested that this route may be particularly appropriate for highly lipophilic drugs like buprenorphine.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7306425      PMCID: PMC1401880          DOI: 10.1111/j.1365-2125.1981.tb01189.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  8 in total

1.  Plasma fentanyl concentrations and clinical observations during and after operation.

Authors:  H J McQuay; R A Moore; G M Paterson; A P Adams
Journal:  Br J Anaesth       Date:  1979-06       Impact factor: 9.166

2.  Kinetics of pharmacologic response. I. Proposed relationships between response and drug concentration in the intact animal and man.

Authors:  J G Wagner
Journal:  J Theor Biol       Date:  1968-08       Impact factor: 2.691

3.  Reversal of postoperative hyperglycaemia by buprenorphine.

Authors:  R A Moore; H J McQuay; R E Bullingham
Journal:  Lancet       Date:  1980-09-13       Impact factor: 79.321

4.  Analgesic effects of sublingual buprenorphine.

Authors:  W G Edge; G M Cooper; M Morgan
Journal:  Anaesthesia       Date:  1979-05       Impact factor: 6.955

5.  Clinical effects of buprenorphine during and after operation.

Authors:  H J McQuay; R E Bullingham; G M Paterson; R A Moore
Journal:  Br J Anaesth       Date:  1980-10       Impact factor: 9.166

6.  Buprenorphine kinetics.

Authors:  R E Bullingham; H J McQuay; A Moore; M R Bennett
Journal:  Clin Pharmacol Ther       Date:  1980-11       Impact factor: 6.875

7.  The radioimmunoassay of buprenorphine.

Authors:  A J Bartlett; J G Lloyd-Jones; M J Rance; I R Flockhart; G J Dockray; M R Bennett; R A Moore
Journal:  Eur J Clin Pharmacol       Date:  1980-10       Impact factor: 2.953

8.  Epidural analgesia improves postoperative nitrogen balance.

Authors:  M R Brandt; A Fernades; R Mordhorst; H Kehlet
Journal:  Br Med J       Date:  1978-04-29
  8 in total
  24 in total

Review 1.  Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence.

Authors:  Alexander Elkader; Beth Sproule
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

2.  Population Pharmacokinetic Model of Sublingual Buprenorphine in Neonatal Abstinence Syndrome.

Authors:  Chee M Ng; Erin Dombrowsky; Hopi Lin; Michelle E Erlich; David E Moody; Jeffrey S Barrett; Walter K Kraft
Journal:  Pharmacotherapy       Date:  2015-07-14       Impact factor: 4.705

Review 3.  Buprenorphine for treating cancer pain.

Authors:  Mia Schmidt-Hansen; Nathan Bromham; Mark Taubert; Stephanie Arnold; Jennifer S Hilgart
Journal:  Cochrane Database Syst Rev       Date:  2015-03-31

4.  Improved buccal delivery of opioid analgesics and antagonists with bitterless prodrugs.

Authors:  M A Hussain; B J Aungst; C A Koval; E Shefter
Journal:  Pharm Res       Date:  1988-09       Impact factor: 4.200

5.  Analgesia in the acute abdomen.

Authors:  B Meiklejohn
Journal:  Ann R Coll Surg Engl       Date:  1987-01       Impact factor: 1.891

6.  Strong analgesics in severe pain.

Authors:  G K Gourlay; M J Cousins
Journal:  Drugs       Date:  1984-07       Impact factor: 9.546

7.  Acute effects of intramuscular and sublingual buprenorphine and buprenorphine/naloxone in non-dependent opioid abusers.

Authors:  Angela N Duke; Christopher J Correia; Sharon L Walsh; George E Bigelow; Eric C Strain
Journal:  Psychopharmacology (Berl)       Date:  2010-06-25       Impact factor: 4.530

8.  Pain in the jungle.

Authors:  G W Hanks
Journal:  Br Med J (Clin Res Ed)       Date:  1988-02-06

Review 9.  Clinical pharmacokinetics of narcotic agonist-antagonist drugs.

Authors:  R E Bullingham; H J McQuay; R A Moore
Journal:  Clin Pharmacokinet       Date:  1983 Jul-Aug       Impact factor: 6.447

10.  Intravenous buprenorphine and norbuprenorphine pharmacokinetics in humans.

Authors:  M A Huestis; E J Cone; S O Pirnay; A Umbricht; K L Preston
Journal:  Drug Alcohol Depend       Date:  2012-12-14       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.